Citadel Advisors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $7.64M | Sell |
57,968
-21,743
| -27% | -$2.88M | ﹤0.01% | 3660 |
|
|
2025
Q4 | $11.3M | Sell |
79,711
-713,528
| -90% | -$103M | ﹤0.01% | 3102 |
|
|
2025
Q3 | $111M | Sell |
793,239
-1,255,836
| -61% | -$170M | 0.02% | 764 |
|
|
2025
Q2 | $258M | Buy |
2,049,075
+1,160,047
| +130% | +$133M | 0.04% | 326 |
|
|
2025
Q1 | $98.3M | Sell |
889,028
-1,649,081
| -65% | -$209M | 0.02% | 706 |
|
|
2024
Q4 | $346M | Buy |
2,538,109
+773,519
| +44% | +$95.7M | 0.06% | 227 |
|
|
2024
Q3 | $203M | Buy |
1,764,590
+1,023,651
| +138% | +$140M | 0.04% | 360 |
|
|
2024
Q2 | $102M | Sell |
740,939
-100,379
| -12% | -$13.8M | 0.02% | 679 |
|
|
2024
Q1 | $116M | Buy |
841,318
+729,318
| +651% | +$99.6M | 0.02% | 615 |
|
|
2023
Q4 | $14.8M | Sell |
112,000
-624,207
| -85% | -$71.9M | ﹤0.01% | 2361 |
|
|
2023
Q3 | $82.8M | Sell |
736,207
-570,066
| -44% | -$60M | 0.02% | 728 |
|
|
2023
Q2 | $123M | Buy |
1,306,273
+831,881
| +175% | +$81.3M | 0.03% | 509 |
|
|
2023
Q1 | $48M | Buy |
474,392
+288,824
| +156% | +$30.1M | 0.01% | 1108 |
|
|
2022
Q4 | $22.2M | Sell |
185,568
-50,078
| -21% | -$5.87M | 0.01% | 1862 |
|
|
2022
Q3 | $25M | Buy |
+235,646
| New | +$23.9M | 0.01% | 1654 |
|
|
2022
Q2 | – | Sell |
-93,098
| Closed | -$8.59M | – | 13678 |
|
|
2022
Q1 | $8.73M | Sell |
93,098
-729,731
| -89% | -$61.8M | ﹤0.01% | 3178 |
|
|
2021
Q4 | $70.1M | Sell |
822,829
-21,172
| -3% | -$1.95M | 0.01% | 911 |
|
|
2021
Q3 | $80.9M | Buy |
844,001
+176,015
| +26% | +$16.6M | 0.02% | 782 |
|
|
2021
Q2 | $65M | Sell |
667,986
-467,361
| -41% | -$44.8M | 0.01% | 931 |
|
|
2021
Q1 | $110M | Sell |
1,135,347
-12,160
| -1% | -$1.28M | 0.03% | 539 |
|
|
2020
Q4 | $110M | Buy |
1,147,507
+836,009
| +268% | +$80.7M | 0.03% | 500 |
|
|
2020
Q3 | $30M | Buy |
311,498
+167,143
| +116% | +$19.3M | 0.01% | 1227 |
|
|
2020
Q2 | $17.6M | Sell |
144,355
-852,854
| -86% | -$94.2M | 0.01% | 1619 |
|
|
2020
Q1 | $86.3M | Buy |
997,209
+573,054
| +135% | +$56.1M | 0.04% | 393 |
|
|
2019
Q4 | $45.6M | Buy |
424,155
+243,978
| +135% | +$25.5M | 0.02% | 825 |
|
|
2019
Q3 | $16.2M | Buy |
180,177
+124,617
| +224% | +$11.6M | 0.01% | 1683 |
|
|
2019
Q2 | $4.69M | Buy |
55,560
+4,770
| +9% | +$392K | ﹤0.01% | 3181 |
|
|
2019
Q1 | $4.47M | Buy |
+50,790
| New | +$4.25M | ﹤0.01% | 3165 |
|
|
2018
Q4 | – | Sell |
-439,598
| Closed | -$42.1M | – | 9541 |
|
|
2018
Q3 | $54M | Buy |
439,598
+23,431
| +6% | +$2.66M | 0.02% | 720 |
|
|
2018
Q2 | $40.9M | Buy |
416,167
+97,981
| +31% | +$8.77M | 0.02% | 817 |
|
|
2018
Q1 | $26.4M | Sell |
318,186
-219,221
| -41% | -$18.5M | 0.01% | 926 |
|
|
2017
Q4 | $41.7M | Buy |
537,407
+320,800
| +148% | +$21.9M | 0.03% | 717 |
|
|
2017
Q3 | $13.3M | Buy |
216,607
+200,055
| +1,209% | +$10.6M | 0.01% | 1370 |
|
|
2017
Q2 | $761K | Sell |
16,552
-961,980
| -98% | -$46.7M | ﹤0.01% | 4513 |
|
|
2017
Q1 | $42.4M | Buy |
978,532
+717,664
| +275% | +$30.7M | 0.04% | 525 |
|
|
2016
Q4 | $10.1M | Sell |
260,868
-776,651
| -75% | -$35.2M | 0.01% | 1353 |
|
|
2016
Q3 | $52.5M | Buy |
1,037,519
+103,974
| +11% | +$5.18M | 0.05% | 366 |
|
|
2016
Q2 | $42.4M | Sell |
933,545
-878,118
| -48% | -$40.4M | 0.05% | 408 |
|
|
2016
Q1 | $71.7M | Buy |
1,811,663
+676,839
| +60% | +$26.9M | 0.09% | 195 |
|
|
2015
Q4 | $64.2M | Buy |
1,134,824
+656,626
| +137% | +$33.4M | 0.07% | 301 |
|
|
2015
Q3 | $19M | Sell |
478,198
-334,286
| -41% | -$16.2M | 0.02% | 943 |
|
|
2015
Q2 | $38.8M | Buy |
812,484
+419,934
| +107% | +$17.8M | 0.03% | 609 |
|
|
2015
Q1 | $15.6M | Sell |
392,550
-725,676
| -65% | -$26M | 0.01% | 1133 |
|
|
2014
Q4 | $25M | Buy |
1,118,226
+182,918
| +20% | +$3.47M | 0.02% | 808 |
|
|
2014
Q3 | $14.7M | Buy |
935,308
+667,174
| +249% | +$9.97M | 0.02% | 1104 |
|
|
2014
Q2 | $3.98M | Buy |
268,134
+224,291
| +512% | +$3.17M | ﹤0.01% | 2041 |
|
|
2014
Q1 | $706K | Buy |
43,843
+3,855
| +10% | +$65.9K | ﹤0.01% | 3876 |
|
|
2013
Q4 | $374K | Buy |
39,988
+37,106
| +1,288% | +$362K | ﹤0.01% | 4365 |
|
|
2013
Q3 | $33K | Sell |
2,882
-13,471
| -82% | -$185K | ﹤0.01% | 5986 |
|
|
2013
Q2 | $219K | Buy |
+16,353
| New | +$201K | ﹤0.01% | 4589 |
|
Other funds holding NBIX
VPM
VCM
Citadel Advisors's NBIX Position: Q1 2026 in Review
Citadel Advisors reduced its Neurocrine Biosciences (NBIX) stake by 27% in Q1 2026, selling an estimated $2.88M and leaving 57,968 shares worth $7.64M. The position accounts for ﹤0.01% of the portfolio, ranked #3660.
Citadel Advisors first reported a position in NBIX in Q2 2013 and has held it in 50 quarters since. The position peaked at $346M in Q4 2024. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Citadel Advisors held 57,968 shares of Neurocrine Biosciences worth $7.64M as of Q1 2026.
- Citadel Advisors sold 21,743 Neurocrine Biosciences shares in Q1 2026, an estimated $2.88M.
- Neurocrine Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3660 holding.
- Citadel Advisors first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 50 quarters since.
- Citadel Advisors's Neurocrine Biosciences position peaked at $346M in Q4 2024.
- 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.